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INTRODUCTION 
Diabetis mellitus is a group of metabolic disorders 
characterized by chronic hyperglycemia associated with 
disturbances of carbohydrate, fat and protein metabolism 
resulting due to absolute or relative deficiency in insulin 
secretion, insulin action or both. Diabetis cause long term 
damage, dysfunction and failure of various organs 
especially the eyes, kidneys, nerves, heart and blood 
vessels. There is an increase in the prevalence of type -1 
diabetis also, but main cause of diabetis epidemic is type-2 
diabetis mellitus, which accounts for more than 90 percent 
of all diabetis cases. The majority of cases of diabetis fall 
into two broad etipathogenetic categories now called type -
1 and type- 2 diabetis mellitus. The etiologic classification 
of diabetis mellitus currently recommended by WHO and 
the ADA in 1997. 
Diagnosis and Clinical Presentation 
 Type 1 Diabetis Mellitus:  Type -1 diabetes mellitus, 
results from insulin deficiency following destruction of the 
insulin-producing pancreatic beta cells and these patients 
depend on insulin for survival. On withdrawl of insulin 
they develop hyperglycemia ,ketoacidosis and coma.It 
most commonly presents in childhood but one-fourth of 
cases are diagnosed in adults. The genetic factors, 
autoimmunity and environmental factors play a role in 
causation and precipitation of type-1diabetis mellitus. 
Symptoms are caused by hyperglycemia and include 
polyuria, polydipsia, and weight loss despite increased 
appetite initially. The absence or poor response of 
glucogon stimulated C peptide levels are diagnostic of 
type-1 diabetis as these patients have low residual beta cell 
function. 
Type 2 Diabetis Mellitus:  T2 diabetis mellitus (T2DM) is 
the most common form of diabetes. The 
pathophysiological basis is a combination of impaired beta 
cell function, with marked increase in peripheral insulin 
resistance at receptor /post receptor levels and increased 
hepatic glucose output production.The risk of developing 
Type – 2 diabetis mellitus increases with age, obesity, 
physical inactivity, and also shows strong familial 
tendency. C-peptide may be variable ranging from hyper to 
normoinsulinemic levels in a majority of the subjects.  
Monitoring Of Blood Glucose  
Blood Glucose Testing: The glucose con-centration is 10-
15 % higher in plasma or serum than in whole blood 
because structural components of blood cells are absent. 
Testing for Ketonuria/Ketonemia 
Most strips utilize a nitroprusside re-action that measures 
only acetone and acetoacetate. Although these tests do not 
detect β-hydroxybutyric acid, the semi quantitative 
estimation of the other ketone bodies is nonethe-less 
usually adequate for clinical assessment of ketonuria. 
Glycosylated Haemoglobin 
The major form of glycohaemoglobin (HbA1C) is 
abnormally elevated in diabetics. Glyco-haemoglobin 
generally reflects the state of glycemia over the preceding 
8-12 weeks, thereby providing a method of assessing 
chronic diabetic control 
1
.  
Management
 
ABSTRACT 
In the management of type-2 diabetis mellitus ie insulin resistance has become easier due to the discovery of  
Thiazolidinediones   (also called Glitazones), other  than Biguanides . However the adverse effects  of Pioglitazone especially 
bladder cancer on long term use had made uncertain future regarding their safety.  Purpose of this review article is to 
understand the pharmacology of Pioglitazone and its current status in India. Data was collected from Review articles, Standard 
pharmacology text books, Pharmacology journals and Electronic data base like Medline. They were analysed and relevant data 
was collected. There is no doubt at all regarding the therapeutic potential of the Glitazone group of drugs. Both Pioglitazone 
and Rosiglitazone have been hugely successful in controlling the HbA1c levels in a large number of patients with type 2 
diabetes. Insulin resistance is more common in Asian indians and hence Glitazones have been very popular in India. However 
the correlation between Pioglitazone and bladder cancer is seen with duration of the therapy more than 24 months and 
cumulative dose of an average daily dose of Pioglitazone of about 40 mg/day. In India, we generally do not use doses greater 
than 30 mg, which means, to achieve a cumulative dose  we would take longer and if we use low dose 7.5 mg Pioglitazone,  
whether  Indians are equally, more, or less, prone to risk of bladder cancer than Europeans has to be further studied. 
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Diabetes mellitus is condition associated with number of 
complications including coronary heart disease, 
retinopathy, neuropathy etc. It is now clear that tight 
control of blood glucose significantly reduces the risk of 
complications of diabetes. 
Management of Type-2 Diabetis Mellitus 
Non-pharmacological Therapy: Non-pharmacological 
measures including diet, exercise and stress alleviation are 
important interventions for the management of diabetes. 
Pharmacological therapy: Monotherapy( single drug ), 
combination of drugs (insulin resistant patients for type-2 
DM) and Insulin (type- 1 DM ). 
PHARMACOLOGICAL THERAPY OF 
PIOGLITAZONE 
It indicated for the treatment of insulin resistant cases. 
Pioglitazone is probably the most potent and effective oral 
drug option among the five available groups, the sixth 
being insulin and the benefits of this 'insulin sensitiser' 
outweighs the risks. 
The Mechanism of Action of Pioglitazone: 
Thiazolidinediones 
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Improved insulin sensitivity 
                               
Thiazolidinediones are selective agonists for the nuclear 
perixosome proliferator –activated receptor ץ (PPARץ ) 
which is expressed mainly in fat cells , but also muscle and 
other cells. It enhances the transcription of several insulin 
responsive genes .Glitazones tend to reverse insulin 
resistance by enhancing GLUT 4 expression and 
translocation. Entry of glucose in to muscle and fat tissue 
is improved. Activation of genes regulating fatty acid 
metabolism and lipogenesis in adipose tissue contributes to 
the insulin sensitizing action. Lipolysis and plasma fatty 
acid levels are reduced. Adipocytes turn over and 
differentiation is accelerated by glitazones. Thus fatty 
tissue is major site of action 
2
. 
THERAPEUTIC USES OF PIOGLITAZONE 
Pioglitazone improved glycaemic control results in 
lowering of circulating HBA1C (by 0.5% - 1.2 %) without 
increasing circulating insulin levels in type-2 diabetis 
mellitus patients. About 25% patients may not respond 
(non-responders), probably due to low baseline insulin 
levels. It should be stopped if HBA1C reduction is less 
than 0.5% at 6 months. Pioglitazone is primarly used to 
supplement Sulfonylureas /Metformin and in case of 
insulin resistance. However, it is not likely to be effective 
when β cell failure has set in, which may be the cause of 
loss of efficacy to a combination of Sulfonylureas 
/Metformin. Glitazones have beneficial effects beyond 
their blood glucose lowering properties 
3
. Monotherapy 
with glitazones is not associated with hypoglycaemic 
episodes 
4
. 
 
Pioglitazone in addition lowers serum TG(26% ↓TG) and 
raises HDL( 14% ↑HDL)level without much change in 
LDL levels, propably because it acts on PPARץ  as well to 
induce expression of reverse cholesterol transporter and 
some apoproteins. One of the largest trials conducted on 
Pioglitazone, PROACTIVE showed that Pioglitazone 
improved glycemic control and additionally suggested a 
possible cardio-protective effect 
5
. The PERISCOPE trial 
also showed that Pioglitazone was associated with 
improvement in CV risk factors and prevention of 
atherosclerosis progression compared to Glimepiride 
6
. In 
the CHICAGO trial, Pioglitazone significantly slowed the 
progression of carotid intima-media thickness (CIMT) 
compared with Glimepiride 
7
.  
The Diabetes Prevention Programme (2005) has shown 
that glitazones have the potential to delay progression of 
pre-diabetics to overt type-2 diabetis mellitus.They may 
help to conserve β cell function in diabetis. Due to their 
remarkable efficacy in terms of glycemic control, they 
became popular and were widely used globally in spite of 
these side effects. 
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ADVERSE EFFECTS OF PIOGLITAZONE  
Pioglitazone is well tolerated however, both Pioglitazone 
and Rosiglitazone had their own spectrum of side effects 
like weight gain, decrease in haematocrit values, edema, 
heart failure, bladder cancer ,fractures and possible 
worsening of diabetic macular edema . 
Heart failure 
In heart failure Thiazolidinediones  have different effect  
on cardiovascular out come.They cause fluid retention, 
edema ,exacerbate pre-existing heart failure but do not 
affect left ventricular function.Fluid retention respond to 
diuretics, perhaps Amiloride or Spironolactone in 
particular.
8,9
 
Indeed, in a detailed analysis of the patients in PROactive 
who developed serious heart failure subsequent all-cause 
mortality was proportionately lower with Pioglitazone 
(40/149 [26.8%] versus 37/108 [34.3%] with placebo; 
p=0.1338). Significantly fewer Pioglitazone patients with 
serious heart failure went on to die, have a non-fatal MI or 
a stroke (34.9% with Pioglitazone versus 47.2% with 
placebo; p=0.025). When considering the matter of heart 
failure in this context it is important to emphasise that the 
Pioglitazone group in general as well as those with serious 
heart failure, had significantly less death, MI and stroke
10
. 
Fractures 
Increased risk of fractures in females (0.8 fractures 
/100patients per year).Distal upper limb is more prone to 
fractures compared to distal lower limb. 
Myocardial infarction 
In patients taking Rosiglitazone increased incidence of 
myocardial infarction has led to drastic decline in the use 
of drug, and it being banned in several countries including 
India 
11
.  
Hepatic dysfunction 
Few cases of hepatic dysfunction have been reported with 
Pioglitazone.Monitering of liver function is advised.It is 
contraindicated in liver disease and in congestive cardiac 
failure 
12
. Pioglitazone is metabolised by both CYP2C8 
and CYP3A4. Failure of oral contraception may occur 
during Pioglitazone therapy. Ketaconazole inhibits and 
Rifampin induce metabolism of Pioglitazone. 
Pregnanacy 
Pioglitazone should not be used during pregnancy because 
of  teratogenecity. 
Bladder Cancer 
Diabetis itself increase risk of cancer including bladder. 
Pioglitazone in Preclinical studies  had shown increased  
incidence of bladder cancer in male rats but initial 
experimental studies suggested that this might be a rat – 
specific phenominan
13
. Indeed PPARγ is currently 
considered a potential target for both chemoprevention and 
cancer therapy based on some preclinical studies
14
 
.Therefore, TZDs like Pioglitazone may increase, decrease 
or have a neutral effect on the risk of cancer or cancer 
progression in different species 
15
 . 
Bladder cancer is estimated to occur in Indian men 4.8 per 
100,000 persons , 20 per 100,000 persons in the US and 
this prevalence is believed to be higher in the US because 
of high dose use , and this is believed to be higher in 
people with diabetes. 
A recent analysis published in Diabetis care, reports on 
data on bladder cancer associated with antidiabetic drug 
use retrieved from the US FDA Adverse Event Reporting 
System (AERS)
16
. 
The Kaiser Permanente study in California, USA22 
included 1,93,099 patients aged ≥40 years of age at study 
entry. The median duration of therapy among 
Pioglitazone-treated patients was 2 years (range 0.2-8.5 
years). The results showed that after adjusting for age, sex, 
use of tobacco products, use of other categories of diabetes 
medications, and other risk factors, the risk of bladder 
cancer increased with increasing dose and duration of 
Pioglitazone use. Patients who were on Pioglitazone 
therapy for longer than 24 months, were found to have a 
40% increased risk of bladder cancer 
17
. 
The US FDA has also asked to revise the patient 
medication guide for Pioglitazone including information 
regarding the increased risk of bladder cancer. FDA has 
further recommended that healthcare professionals should 
not use Pioglitazone in patients with active bladder cancer 
and to use it with caution in patients with a prior history of 
bladder cancer. Finally, the FDA has stated that additional 
information should be provided to patients stating that they 
should report to a physician if there are any symptoms of 
bladder cancer such as blood or red color in urine, urgent 
need to urinate or pain while urinating, pain in back or 
lower abdomen. 
A Canadian team of researchers decided to investigate if 
Pioglitazone was linked to a higher risk of bladder cancer 
in people with type 2 diabetes and after obtaining data 
from the General Practice Research Database (GPRD), 
they evaluated 115,727 patients who initiated diabetes 
therapy from 1988 to 2009. The GPRD contains 
anonymous patient records from over 600 UK GPs. The 
team identified cases of bladder cancer and matched them 
to up to 20 healthy control patients.   
The results revealed that from 376 cases that were matched 
against 6,699 controls, 470 patients were diagnosed with 
bladder cancer during the average 4.6 years of follow-up, 
which translates to a rate of 89 per 100,000 person years, 
whilst the rate of bladder cancer in the general UK 
population aged 65 years and above is 73 per 100,000 
person years.    
Patients who had taken Pioglitazone at any time were 
found to have a 83% higher risk of bladder cancer, which 
translates into 74 per 100,000 person years. The figures 
increased to 88 per 100,000 person years for those who 
had taken the drug for two years or longer and increased 
even further, to 137 per 100,000 person years those who 
had taken 28,000mg or more. 
Researchers cross-checked the results in several further 
analyses, but the results remained consistent, and "provide 
evidence that Pioglitazone is associated with an increased 
risk of bladder cancer, whereas no increased risk was 
observed with the Thiazolidinedione Rosiglitazone." 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They believe that these links may have been 
underestimated during earlier observational studies and 
comment that doctors, patients and regulatory agencies 
"should be aware of this association when assessing the 
overall risks and benefits of this therapy."   
Safety and efficacy of low dose Pioglitazone (7.5mg/day) 
vs standard dose (15mg/day) in Japanese women with 
type-2 diabetis mellitus suggested low dose Pioglitazone 
could be a good choice for type-2 diabetis mellitus in 
Japanese women.The incidence of peripheral edema in 
group A (with low dose) was low when compared with 
group –B .In addition % change of body weight in group –
A was significantly less than group 
18
. 
In contrast, the European Medical Agency alert concludes 
that the benefit/risk balance remains positive in favour of 
Pioglitazone in a limited population of patients with type 2 
diabetes and that the small increased risk of bladder cancer 
could be reduced by appropriate patient selection. 
However, this agency also recognizes the need for periodic 
review of the efficacy and safety of the individual patient’s 
treatment. 
CURRENT STATUS OF PIOGLITAZONE IN INDIA: 
With the recent ban of the popular drug Pioglitazone  by 
the health ministry in 2013, there are number of questions 
about the reasons for their ban. One reason is the 
correlation between Pioglitazone and bladder cancer is 
seen with duration of the therapy more than 24 months and 
a cumulative dose of more than 28,000 mg which 
corresponds to an average daily dose of pioglitazone of 
about 40 mg/day. The doses used in US and Europe are 
30-45 mg/day. In India, we generally do not use doses 
greater than 30 mg, which means, to achieve a cumulative 
dose of 28,000 mg, we would take longer and if we use 
low dose (7.5 mg) Pioglitazone, it would take about 10 
years. Indeed, low dose Pioglitazone has of late become 
very popular in India due to its efficacy and lower 
frequency of side effects like weight gain and fluid 
retention. However, we do not know whether Indians are 
equally, more, or less, prone to risk of bladder cancer than 
Europeans. 
As per the research reports from various diabetis  research 
centres in India, eight cases of bladder cancer in patients 
with type- 2 diabetes on Pioglitazone have been reported. 
Three of the patients were from Chennai, two from Salem 
and one each from Belgaum, Hyderabad and Mumbai. 
Seven of the eight patients were males. The patients 
ranged in age from 43 years to 76 years. They all had type 
2 diabetes and were on Pioglitazone for periods ranging 
from two to nine years. 
"The mean dose of Pioglitazone ranged from 15 mg to 30 
mg per day. While seven patients had transitional cell 
(urothelial) carcinoma on biopsy, the nature of malignancy 
was not clear in the eighth patient. Seven patients are 
presently on follow-up with urologists and oncologists, 
whereas the eighth patient developed metastases to the 
liver and lungs and died in November 2011 after several 
cycles of chemotherapy and two surgeries. The single 
female patient developed bladder cancer seven years ago 
while on 30 mg of Pioglitazone." 
"She underwent surgery for the same in the US and was 
declared free of malignancy. Since the link of Pioglitazone 
with bladder cancer was not known at that time, she was 
continued on Pioglitazone even after the surgery. She 
developed recurrence of haematuria and pain four months 
later and had to undergo repeat surgery and 
chemotherapy." 
"This is, to the best of our knowledge, the first report on 
bladder cancer among Pioglitazone users in India and one 
of the first in a female patient. Although one cannot draw 
any conclusions of causality from these eight cases, the 
development of this relatively uncommon malignancy in 
eight patients who were on this particular drug does raise 
concern about the long-term safety of Pioglitazone. 
Clinicians should therefore exercise extreme caution in the 
use of this drug. Patients should be made aware of this 
potential side-effect of Pioglitazone and should be allowed 
to make informed choices regarding its use,"  
The US Food and Drug Administration warned in June 
2011 that taking Pioglitazone for at least a year increased 
the risk of bladder cancer by at least 40%, and ordered the 
drug's manufacturer to note the risk on the drug's label. 
The drug is banned in some places like France and 
Germany.  
Cancer as adverse effects of many drugs is difficult to 
prove for several reasons. Cancers have multifocal 
etiologies like genetic interactions, exposure to chemicals, 
environmental factors, diagnosed after considerable time 
has passed. All thse factors make it impossible to point out 
a certain drug as a potential carcinogenic drug. 
For the possible risk of bladder cancer with Pioglitazone 
physicians have to be careful and explain to patients 
regarding risk of bladder cancer. When prescribing 
Pioglitazone it should be started with low dose of 
7.5mg/day and should not exceed maximum dose of 15 
mg/day (toxic doses for bladder cancer in India as reported 
between 15mg to 30mgper day). If blood sugar is not 
controlled with maximum dose of 15mg/day add on 
therapy with other ‘insulin sensitiser' drug can be done. 
Other risk factors are whether there is a history of any 
cancer in the family or patient he has cancer should be 
considered and drug should be withdrawn. 
Councel patients to report any signs or symptoms of blood 
in the urine, urinary urgency, pain on urination, or back or 
abdominal pain, as these may be due to bladder cancer. 
Prescribers are advised not to use these medications in 
patients with current or history of bladder cancer or in 
patients with uninvestigated macroscopic haematuria.They 
should also consider the age of patient and review the 
treatment after 3 to 6 months and regularly after wards. 
SUMMARY AND CONCLUSION  
In India we require more studies for risk of bladder cancer 
with Pioglitazone, till that time , we may continue to use 
low dose of 7.5mg  and dose should not exceed 15 mg/day  
as it is a very good 'insulin sensitiser'  and benefit ratio 
outweighs risk ratio as glucose lowering agent.The patient 
should also be informed about adverse effects of the drug 
with careful monitoring and follow up. At present there is 
on-going discussion by the ministry of health in India on 
the Pioglitazone ban taking views from different 
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diabetoligists and general practioners all over India 
regarding the ban of the drug, and in the future the ban 
may be revoked. 
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